Departments of Pathology, Gynecology and Obstetrics and Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Am J Surg Pathol. 2010 Mar;34(3):433-43. doi: 10.1097/PAS.0b013e3181cf3d79.
Ovarian cancer is the most lethal gynecologic malignancy. Efforts at early detection and new therapeutic approaches to reduce mortality have been largely unsuccessful, because the origin and pathogenesis of epithelial ovarian cancer are poorly understood. Despite numerous studies that have carefully scrutinized the ovaries for precursor lesions, none have been found. This has led to the proposal that ovarian cancer develops de novo. Studies have shown that epithelial ovarian cancer is not a single disease but is composed of a diverse group of tumors that can be classified based on distinctive morphologic and molecular genetic features. One group of tumors, designated type I, is composed of low-grade serous, low-grade endometrioid, clear cell, mucinous and transitional (Brenner) carcinomas. These tumors generally behave in an indolent fashion, are confined to the ovary at presentation and, as a group, are relatively genetically stable. They lack mutations of TP53, but each histologic type exhibits a distinctive molecular genetic profile. Moreover, the carcinomas exhibit a shared lineage with the corresponding benign cystic neoplasm, often through an intermediate (borderline tumor) step, supporting the morphologic continuum of tumor progression. In contrast, another group of tumors, designated type II, is highly aggressive, evolves rapidly and almost always presents in advanced stage. Type II tumors include conventional high-grade serous carcinoma, undifferentiated carcinoma, and malignant mixed mesodermal tumors (carcinosarcoma). They displayTP53 mutations in over 80% of cases and rarely harbor the mutations that are found in the type I tumors. Recent studies have also provided cogent evidence that what have been traditionally thought to be primary ovarian tumors actually originate in other pelvic organs and involve the ovary secondarily. Thus, it has been proposed that serous tumors arise from the implantation of epithelium (benign or malignant) from the fallopian tube. Endometrioid and clear cell tumors have been associated with endometriosis that is regarded as the precursor of these tumors. As it is generally accepted that endometriosis develops from endometrial tissue by retrograde menstruation, it is reasonable to assume that the endometrium is the source of these ovarian neoplasms. Finally, preliminary data suggest that mucinous and transitional (Brenner) tumors arise from transitional-type epithelial nests at the tubal-mesothelial junction by a process of metaplasia. Appreciation of these new concepts will allow for a more rationale approach to screening, treatment, and prevention that potentially can have a significant impact on reducing the mortality of this devastating disease.
卵巢癌是最致命的妇科恶性肿瘤。尽管人们努力进行早期检测并采用新的治疗方法来降低死亡率,但收效甚微,因为人们对卵巢上皮癌的起源和发病机制仍知之甚少。尽管有许多研究仔细检查了卵巢中的前驱病变,但均未发现。这导致了卵巢癌是从头发生的假说。研究表明,卵巢上皮癌不是一种单一的疾病,而是由一组不同的肿瘤组成,这些肿瘤可以根据独特的形态和分子遗传学特征进行分类。一组肿瘤被指定为 I 型,由低级别浆液性、低级别子宫内膜样、透明细胞、黏液性和移行性(Brenner)癌组成。这些肿瘤通常表现为惰性,在出现时局限于卵巢,并且作为一个整体,相对遗传上稳定。它们缺乏 TP53 的突变,但每种组织学类型都表现出独特的分子遗传学特征。此外,这些癌与相应的良性囊性肿瘤具有共同的谱系,通常通过中间(交界性肿瘤)步骤,支持肿瘤进展的形态连续性。相比之下,另一组肿瘤被指定为 II 型,具有高度侵袭性,快速演变,几乎总是在晚期出现。II 型肿瘤包括传统的高级别浆液性癌、未分化癌和恶性混合性苗勒管肿瘤(癌肉瘤)。它们在超过 80%的病例中显示 TP53 突变,很少携带在 I 型肿瘤中发现的突变。最近的研究还提供了有力的证据,证明传统上被认为是原发性卵巢肿瘤的实际上起源于其他盆腔器官,并继发累及卵巢。因此,有人提出浆液性肿瘤起源于输卵管上皮(良性或恶性)的植入。子宫内膜样和透明细胞肿瘤与被认为是这些肿瘤前驱的子宫内膜异位症有关。由于普遍认为子宫内膜异位症是通过逆行月经从子宫内膜组织发展而来的,因此可以合理地假设子宫内膜是这些卵巢肿瘤的来源。最后,初步数据表明,黏液性和移行性(Brenner)肿瘤起源于输卵管-间皮交界处的移行型上皮巢,通过化生过程发生。认识到这些新概念将有助于更合理地进行筛查、治疗和预防,这可能会对降低这种毁灭性疾病的死亡率产生重大影响。